Inogen Inc reported second-quarter revenue of $95.1 million, reflecting a 3% year-over-year growth. The increase supports investor confidence as the firm raises its full-year adjusted EBITDA guidance to $4 million, showcasing improved profitability despite a continuing net loss.

Key Highlights

  • Inogen Inc (NASDAQ: INGN) achieved $95.1 million in revenue for the second quarter ending June 30, 2026, marking a 3% increase from $92.3 million during the same period last year.
  • The company generated $95.1 million in revenue, with international sales accounting for $41.3 million, an impressive 14.8% increase year-over-year.
  • Inogen's recent results underline its strategic focus on expanding its product offerings and enhancing operational leverage.

Inogen Inc (NASDAQ: INGN) achieved $95.1 million in revenue for the second quarter ending June 30, 2026, marking a 3% increase from $92.3 million during the same period last year. This growth comes as the company's earnings per share aligned positively, reporting at $-0.14 compared to a consensus estimate of $-0.16. The steady uptick in revenue indicates growing demand for Inogen's portable oxygen concentrators, particularly in international market segments.

Such performance suggests resilience in a challenging industry environment, boosting investor outlook.

Financial Performance Details

The company generated $95.1 million in revenue, with international sales accounting for $41.3 million, an impressive 14.8% increase year-over-year. The total gross margin improved to 45.5% compared to 44.8% a year prior, indicating better cost management and operational efficiency. Inogen reported a GAAP net loss of $3.9 million, an improvement from the $4.2 million loss reported last year.

The adjusted EBITDA stood at $2.4 million, reflecting a year-over-year increase of 15.2%. The $7.5 million spent on share repurchases represents about 4% of Inogen's $176 million market capitalization, reflecting an ongoing commitment to enhancing shareholder value.

Strategic Update and Market Position

Inogen's recent results underline its strategic focus on expanding its product offerings and enhancing operational leverage. Also, Inogen has progressed in clinical trials, with enrollment completed for its Simeox H SCOPE Study in China, signaling serious intent in global market expansion. Continuous investment in product innovation and diversification is essential to maintain competitive positioning as market dynamics evolve.

Guidance and Future Expectations

Looking ahead, Inogen has adjusted its full-year revenue guidance to between $355 million and $361 million, indicating approximately 3% growth. For the full year, the expected adjusted EBITDA has been raised to approximately $4 million, a considerable 48.1% increase from the $2.7 million reported in 2025. The company's forecast for the third quarter implies steady performance aligned with previous figures, taking into account sales channel dynamics and inventory fluctuations among international distributors.

Investors are advised to tune into the conference call on August 6, 2026, for additional insights on strategic priorities and further financial outlook.

Analysis based on the Form 8-K filed 6 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.